Longitudinal observational study of boxing therapy in Parkinson’s disease, including adverse impacts of the COVID-19 lockdown
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Longitudinal observational study of boxing therapy in Parkinson’s disease, including adverse impacts of the COVID-19 lockdown ; volume:21 ; number:1 ; day:24 ; month:8 ; year:2021 ; pages:1-10 ; date:12.2021
BMC neurology ; 21, Heft 1 (24.8.2021), 1-10, 12.2021
- Urheber
-
Horbinski, Craig
Zumpf, Katelyn B.
McCortney, Kathleen
Eoannou, Dean
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-021-02359-6
- URN
-
urn:nbn:de:101:1-2021110918251607001189
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Horbinski, Craig
- Zumpf, Katelyn B.
- McCortney, Kathleen
- Eoannou, Dean
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lockdown effects on Parkinson’s disease during COVID-19 pandemic: a pilot study
Impact of social and mobility restrictions in Parkinson’s disease during COVID-19 lockdown
Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients
Cardiovascular history and risk of idiopathic Parkinson’s disease: a cross-sectional observational study
Parkinson
Parkinson
Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Neuroplasticity in Parkinson’s disease
Lockdown effects on Parkinson’s disease during COVID-19 pandemic: a pilot study
Impact of social and mobility restrictions in Parkinson’s disease during COVID-19 lockdown
Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients
Cardiovascular history and risk of idiopathic Parkinson’s disease: a cross-sectional observational study
Parkinson
Parkinson
Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Neuroplasticity in Parkinson’s disease
Lockdown effects on Parkinson’s disease during COVID-19 pandemic: a pilot study
Impact of social and mobility restrictions in Parkinson’s disease during COVID-19 lockdown
Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients
Cardiovascular history and risk of idiopathic Parkinson’s disease: a cross-sectional observational study
Parkinson
Parkinson
Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease